{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T11:47:13Z","timestamp":1771760833355,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.acuro.2012.09.001","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T20:08:45Z","timestamp":1355429325000},"page":"292-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Avances en la prevenci\u00f3n y el tratamiento de las met\u00e1stasis \u00f3seas en c\u00e1ncer de pr\u00f3stata. Papel de la inhibici\u00f3n de RANK\/RANKL"],"prefix":"10.1016","volume":"37","author":[{"given":"F.","family":"Gomez-Veiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ponce-Reixa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Martinez-Breijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Morote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2012.09.001_bib0005","unstructured":"Cancer Incidence, mortality and prevalence worldwide in 2008. Globocan 2008 [consultado 29 Dic 2011]. Disponible en: http:\/\/globocan.iarc.fr\/"},{"key":"10.1016\/j.acuro.2012.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.acuro.2011.01.008","article-title":"P\u00e9rdida de masa \u00f3sea en pacientes con c\u00e1ncer de pr\u00f3stata sometidos a deprivaci\u00f3n androg\u00e9nica","volume":"35","author":"Morote","year":"2011","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2012.09.001_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"De Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acuro.2012.09.001_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: from primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett"},{"issue":"20 Pt 2","key":"10.1016\/j.acuro.2012.09.001_bib0045","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00002820-200004000-00005","article-title":"Metastatic bone pain. Meanings associated with self-report and self-management decision making","volume":"23","author":"Coward","year":"2000","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.acuro.2012.09.001_bib0060","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0065","first-page":"869","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.acuro.2012.09.001_bib0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.acuro.2012.09.001_bib0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1191\/0269216305pm1079oa","article-title":"Painful bone metastases: a prospective observational cohort study","volume":"19","author":"Clare","year":"2005","journal-title":"Palliat Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0080","first-page":"163","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0885-3924(98)00069-4","article-title":"Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases","volume":"16","author":"Janjan","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.acuro.2012.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/sj.bjc.6601810","article-title":"Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer","volume":"90","author":"Di Maio","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.acuro.2012.09.001_bib0095","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1359\/JBMR.041133","article-title":"Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures","volume":"20","author":"Jiang","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/bmj.38643.663843.55","article-title":"Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study","volume":"331","author":"Roche","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.acuro.2012.09.001_bib0105","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the U.S.","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2012.09.001_bib0110","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3928\/01477447-20111021-21","article-title":"Update on the pharmacological prevention of skeletal-related events in cancer patients","volume":"34","author":"Kennedy","year":"2011","journal-title":"Orthopedics"},{"key":"10.1016\/j.acuro.2012.09.001_bib0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.acuro.2012.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.acuro.2012.09.001_bib0125","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0130","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.acuro.2012.09.001_bib0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2004.04.022","article-title":"Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer","volume":"46","author":"Montague","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0140","first-page":"1089","article-title":"Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells","volume":"29","author":"Tanaka","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/02841860510029617","article-title":"Additive\/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid","volume":"44","author":"Ullen","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acuro.2012.09.001_bib0155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acuro.2012.09.001_bib0160","first-page":"215","article-title":"Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis","volume":"2","author":"Cozar","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.acuro.2012.09.001_bib0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuro.2012.09.001_bib0175","unstructured":"NCCN Guidelines in Oncology. Prostate Cancer. Version 4.2011. National Comprehensive Cancer Network, 2011 [consultado 30 Jan 2012]. Disponible en: www.nccn.org"},{"key":"10.1016\/j.acuro.2012.09.001_bib0180","first-page":"501","article-title":"Gu\u00eda de la EAU sobre el c\u00e1ncer de pr\u00f3statprostate. Parte I: cribado, diagn\u00f3stico y tratamiento del c\u00e1ncer cl\u00ednicamente localizado","volume":"35","author":"Heidenreich","year":"2011","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2012.09.001_bib0185","unstructured":"ZOMETA: ficha t\u00e9cnica [consultado 30 Jan 2012]; Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/000336\/WC500051730.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.critrevonc.2007.07.005","article-title":"Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?","volume":"64","author":"Diel","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF02409454","article-title":"Role of osteoblasts in hormonal control of bone resorption--a hypothesis","volume":"33","author":"Rodan","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.acuro.2012.09.001_bib0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.acuro.2012.09.001_bib0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.acuro.2012.09.001_bib0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.acuro.2012.09.001_bib0215","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.acuro.2012.09.001_bib0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","article-title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures","volume":"246","author":"Matsuzaki","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.acuro.2012.09.001_bib0225","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0235","article-title":"PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone","author":"Cowan","year":"2011","journal-title":"J Orthop Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.acuro.2012.09.001_bib0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0250","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.acuro.2012.09.001_bib0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.acuro.2012.09.001_bib0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.acuro.2012.09.001_bib0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12094-011-0646-5","article-title":"RANKL inhibition: a promising novel strategy for breast cancer treatment","volume":"13","author":"Gonzalez-Suarez","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0270","unstructured":"Prolia: EPAR - Public assessment report [consultado 24 Oct 2011]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001120\/WC500093529.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0275","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.acuro.2012.09.001_bib0280","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1569-9056(11)61070-1","article-title":"Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: results from a phase 3 trial of denosumab vs. zoledronic acid","volume":"10","author":"Brown","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.acuro.2012.09.001_bib0285","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0290","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0295","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0300","unstructured":"XGEVA: Prescribing information [consultado 30 Jan 2012]. Disponible en: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/125320s007lbl.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.critrevonc.2012.01.002","article-title":"Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer","volume":"83","author":"Climent","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.acuro.2012.09.001_bib0310","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ctrv.2008.03.008","article-title":"Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone","volume":"34","author":"Lipton","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.acuro.2012.09.001_bib0315","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.acuro.2012.09.001_bib0320","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/jco.2012.30.15_suppl.4510","article-title":"Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0325","doi-asserted-by":"crossref","first-page":"LBA4512","DOI":"10.1200\/jco.2012.30.18_suppl.lba4512","article-title":"Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1479-5876-2-16","article-title":"Endothelin receptors as novel targets in tumor therapy","volume":"2","author":"Bagnato","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.acuro.2012.09.001_bib0335","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cbt.8.8.7922","article-title":"Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles","volume":"8","author":"Weydert","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.acuro.2012.09.001_bib0340","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2012.09.001_bib0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/jco.2011.29.7_suppl.117","article-title":"Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC)","volume":"29","author":"Nelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0350","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind. placebo-controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0355","unstructured":"Regeneron Pharmaceuticals, Inc. Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP\u00ae (aflibercept) 2012. Nota de prensa [consultado 31 May 2012]. Disponible en: http:\/\/investor.regeneron.com\/releasedetail.cfm?releaseid=661995"},{"key":"10.1016\/j.acuro.2012.09.001_bib0360","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.eururo.2011.04.038","article-title":"New therapies for castration-resistant prostate cancer: efficacy and safety","volume":"60","author":"Beltran","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0365","unstructured":"JEVTANA: ficha t\u00e9cnica [consultado 30 Jan 2012]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002018\/WC500104764.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0370","unstructured":"ZYTIGA: ficha t\u00e9cnica [consultado 30 Jan 2012]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002321\/WC500112858.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0375","unstructured":"PROVENGE\u00ae (sipuleucel-T). Prescribing information [consultado 30 Jan 2012]. Disponible en: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM210031.pdf"},{"key":"10.1016\/j.acuro.2012.09.001_bib0380","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/jco.2012.30.5_suppl.lba1","article-title":"Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2012.09.001_bib0385","unstructured":"XGEVA: ficha t\u00e9cnica [consultado 30 Jan 2012]. Disponible en: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf>"},{"key":"10.1016\/j.acuro.2012.09.001_bib0390","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480612003282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480612003282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:33:53Z","timestamp":1759322033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480612003282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0210480612003282"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2012.09.001","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avances en la prevenci\u00f3n y el tratamiento de las met\u00e1stasis \u00f3seas en c\u00e1ncer de pr\u00f3stata. Papel de la inhibici\u00f3n de RANK\/RANKL","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2012.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 AEU. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}